IBB0979 not checked

SUNHO(China)BioPharmaceutical CO., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“bifunctional antibody-cytokine fusion protein that targets B7-H3 and IL-10 receptor”In the company’s words, NCT07076095 on ClinicalTrials.gov
Tested for
Small Cell Lung Cancer, Advanced Malignant Tumors
Main trialPhase 2
“This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).”In the company’s words, NCT07076095 on ClinicalTrials.gov

Other drugs for Small Cell Lung Cancer

All 118 drugs for Small Cell Lung Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting 1 Aug 2028 A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
Phase 1/2Recruiting 30 Nov 2025 A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IBB0979

Following is part of Solo: you see every change to IBB0979 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in